Nutraceutical or pharmaceutical composition for use in the treatment of polycystic ovary syndrome or of diseases or disorders related thereto

Abstract

A pharmaceutical or nutraceutical composition having at least one inositol and resveratrol for use in a) preventive and/or curative treatment in metabolic disorders related to polycystic ovary syndrome; b) treatment to reduce symptoms associated with polycystic ovary syndrome such as menstrual cycle alterations and infertility; and/or c) to decrease glucose, triglyceride and BMI levels in subjects with metabolic syndrome.

1 . (canceled) 
     
     
         2 . A method for treating a subject, the method comprising:
 administering to the subject a pharmaceutical or nutraceutical composition comprising   myo-inositol and D-chiro-inositol and resveratrol coprecipitated with or supported on magnesium hydroxide   in an effective amount to reduce menstrual cycle alterations and/or infertility associated with polycystic ovary syndrome.   
     
     
         3 . (canceled) 
     
     
         4 . The method according to  claim 2 , wherein the molar ratio of [myo-inositol] in a range from 0.01 to 100. 
     
     
         5 . The method Composition according to  claim 2  wherein the pharmaceutical or nutraceutical composition comprises from 24% to 90% by weight based on the total weight of the composition of myo-inositol and D-chiro-inositol and from 1% to 10% by weight based on the total weight of the composition of resveratrol. 
     
     
         6 . (canceled) 
     
     
         7 . The method according to  claim 2 , wherein the pharmaceutical or nutraceutical composition comprises myo-inositol and D-chiro-inositol in a molar ratio comprised from 1 to 5. 
     
     
         8 . The method according to  claim 2 , wherein the pharmaceutical or nutraceutical composition further comprises at least one component chosen from the group consisting of lipoic acid, folic acid, vitamin D, and manganese. 
     
     
         9 . The method according to 8, wherein the content of folic acid is comprised from 0.001% to 0.1% by weight based on the total weight of the composition. 
     
     
         10 . The method according to  claim 2 , wherein the pharmaceutical or nutraceutical composition prepared in form
 of a solid preparation for oral and buccal use selected from powders, granules, capsules, pills, chewing gums, bolus, cachets, tablets, lozenges, and medicinal chocolates.   
     
     
         11 . The method according to  claim 2 , wherein the molar ratio of [myo-inositol]/[D-chiro-inositol] in the in the pharmaceutical or nutraceutical composition is between 1 and 5. 
     
     
         12 . The method according to  claim 2 , wherein the molar ratio of [myo-inositol] [D-chiro-inositol] in the pharmaceutical or nutraceutical composition is less than 2.5. 
     
     
         13 . The method according to  claim 2 , wherein the molar ratio of [myo-inositol] [D-chiro-inositol] in the pharmaceutical or nutraceutical composition is between 0.001 and 07. 
     
     
         14 . The method according to  claim 2 , wherein the molar ratio of [myo-inositol]/[D-chiro-inositol] in the pharmaceutical or nutraceutical composition is 0.4. 
     
     
         15 . The method according to  claim 2 , wherein the pharmaceutical or nutraceutical composition further comprise vitamin D3 from 0.00015 to 0.1% by weight based on the total weight of the composition. 
     
     
         16 . The method according to  claim 2 , wherein the pharmaceutical or nutraceutical composition further comprise manganese from 0.001% to 5% by weight based on the total weight of the composition. 
     
     
         17 . The method according to  claim 7 , wherein the myo-inositol and D-chiro-inositol in the pharmaceutical or nutraceutical composition is in a molar ratio less than 2.5. 
     
     
         18 . The method according to  claim 7 , wherein the myo-inositol and D-chiro-inositol in the pharmaceutical or nutraceutical composition is in a molar ratio between 0.001 and 0.7. 
     
     
         19 . The method according to  claim 7 , wherein the myo-inositol and D-chiro-inositol in the pharmaceutical or nutraceutical composition is in a molar ratio of 0.4. 
     
     
         20 . The method according to  claim 2 , wherein the pharmaceutical or nutraceutical composition is prepared in a form of liquid/semisolid preparation for oral use selected from the group consisting of syrups, elixirs, pastes, juices, decoction, suspensions, emulsions, mucilages, herbal teas, medicinal wines, and potions. 
     
     
         21 . The method according to  claim 2 , wherein the pharmaceutical or nutraceutical composition is in a form for skin applications selected from the group consisting of creams, ointments, gels, emulsions, lotions, linings, medicinal soaps, medicinal shampoos, non-medical shampoos, skin pencils, poultice, gums, oils, oleolites, ointments, dyes, and medicated gauzes. 
     
     
         22 . The method according to  claim 2 , wherein the pharmaceutical or nutraceutical composition is prepared in a form of ear, nasal and mucous membrane preparations selected from the group consisting of collutories, gargles, ear washings, ear cuffs, nasal washings, tampons, oils, oleolites, emulsions, ointments, gels, emulgel, lipogels, tablets, capsules, films, and medicated plasters. 
     
     
         23 . The method according to  claim 2 , wherein the pharmaceutical or nutraceutical composition is prepared in a form of ophthalmic preparations selected from the group consisting of eye drops, ophthalmic inserts and ocular baths. 
     
     
         24 . The method according to  claim 2 , wherein the pharmaceutical or nutraceutical composition is prepared in a form for administration through the lower (anal and vaginal) cavities selected from the group consisting of suppositories, capsules, tablets, enemas, medical irrigation, lavages, foams, tampons, pessary, ovule drugs, foams, gels, pastes, emulsion, creams, ointments, films, suspensions, wraps, plasters, rings, and medicated gauzes. 
     
     
         25 . The method according to  claim 2 , wherein the pharmaceutical or nutraceutical composition is prepared in a form of spray preparation for topical, inhalation, oral, and buccal use.